SYSTEMIC LUPUS ERYTHEMATOSUS

This early-stage study tests a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't responded to standard therapies. CNTY-101 uses specially engineered immune cells to target and destroy faulty …

This study tests whether lisinopril, a common blood pressure medicine that works in the brain, can improve memory and concentration problems in people with lupus. About 36 adults with lupus will take either lisinopril or another similar drug for 12 months. Researchers will measur…

This early-stage study tests a new treatment called RD06-04, which uses a patient's own immune cells modified to target and destroy faulty B cells. It aims to control active autoimmune diseases like lupus, scleroderma, and Sjögren's syndrome. The main goal is to check safety, but…

This early-stage study tests a new treatment called SC291 for people with severe lupus or vasculitis that hasn't responded to other therapies. SC291 uses specially designed immune cells from a donor to target and attack faulty immune cells driving the disease. The main goal is to…

This study was designed to test whether the drug telitacicept could help people with moderate-to-severe lupus, an autoimmune disease that causes inflammation and organ damage. It planned to enroll around 400 participants aged 12 to 70. However, the trial was withdrawn before any …

This early-phase study tests a new treatment called KITE-363 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myositis that haven't improved with standard therapies. KITE-363 uses a patient's own immune cells, modified to target and destroy fau…

This study tests a new medicine called ianalumab for people with active lupus, an autoimmune disease that causes inflammation and damage. About 436 participants will receive either ianalumab or a placebo as monthly or quarterly shots, added to their usual treatments. The goal is …

This study compares two ways of giving the drug ianalumab to adults with rheumatoid arthritis, Sjögren's disease, or lupus. One group gets one injection from a 2mL auto-injector, the other gets two separate 1mL shots. The goal is to see if the single injection works just as well …

This study follows about 551 people with systemic lupus erythematosus (SLE) who are starting a new treatment called anifrolumab. Researchers want to see how well the drug controls disease activity and improves quality of life in routine medical practice, not just in a controlled …

This phase 3 study tests whether upadacitinib, a drug already approved for other autoimmune diseases, can safely control moderate-to-severe lupus. About 1,000 adults with lupus will take either the study drug or a placebo daily for a year. The goal is to see if the drug reduces d…

This study was designed to test a single infusion of CB-010, a CRISPR-edited immune cell therapy, in people with severe lupus that did not respond to standard treatments. The trial was withdrawn before enrolling any participants, so no results are available. It aimed to check saf…

This study looks back at medical records of 180 adults with lupus to compare two drugs: telitacicept and belimumab. The goal is to see which one works better at controlling the disease and has fewer side effects. Participants are not given any new treatment—researchers simply ana…

This study tests whether the drug deucravacitinib can safely control symptoms of moderate-to-severe systemic lupus erythematosus (SLE) better than a placebo. About 513 adults with active lupus will take either the drug or a dummy pill for several months. The main goal is to see i…

This study looks at the long-term safety of the drug enpatoran in people with lupus who have already finished a 24-week treatment in a previous study. About 379 participants will take the drug by mouth to see how well it controls their disease over time. The goal is to monitor si…

This study tests a new medicine called SAR441344 in people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 109 adults aged 18-70 will receive either the drug or a placebo for 24 weeks to see if it reduces lupus symptoms without causing serious …

This early-stage study tests a new treatment for people with severe lupus or scleroderma that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system. The main goal is to check safety and f…

This study tests a new drug called MIL62 in 120 adults with active systemic lupus erythematosus (SLE), an autoimmune disease. The goal is to see if MIL62 can reduce disease activity better than a placebo over 12 weeks, with long-term follow-up up to 76 weeks. Participants must ha…

This early-stage trial tests a treatment called YTB323 in about 21 adults with severe lupus that hasn't responded to other therapies. The goal is to see if it is safe and can help control the disease. Participants receive the therapy and are followed for side effects and how long…

This early-stage study tests whether a special type of immune cell, called a CAR-T cell, is safe for people with severe lupus that hasn't responded to standard treatments. The cells are designed to target and destroy faulty immune cells that cause lupus. The study includes 22 par…

This study tests a new treatment using specially engineered immune cells (CAR T-cells) from a donor to target and calm the overactive immune system in people with severe lupus or scleroderma. The goal is to see if it is safe and can reduce disease activity. 18 adults who have not…

This study tests an experimental pill called deucravacitinib against a placebo in 516 people with active moderate-to-severe systemic lupus erythematosus (SLE). The goal is to see if the drug can reduce lupus disease activity better than a dummy pill. Participants must have had lu…

This study tests an experimental drug called obinutuzumab in 303 people with active lupus. The drug targets immune cells to reduce disease flares. Participants receive either the drug or a placebo, plus their usual treatments. The main goal is to see if more people achieve a sign…

This early-phase study tests a new treatment called NKX019 for people with lupus, an autoimmune disease. NKX019 uses specially engineered immune cells to target and calm overactive B cells. The main goal is to check safety in 6 adults, while also seeing if it reduces lupus sympto…

This study tests a new injectable drug, anifrolumab, for adults with moderate-to-severe systemic lupus erythematosus (SLE) who are already on standard treatments. The goal is to see if adding anifrolumab can better control lupus activity and reduce flare-ups. About 367 participan…

This study tests a drug called belimumab, given as a shot under the skin, in children aged 5 to 17 with lupus. The goal is to see how the drug behaves in the body and if it is safe when used with standard treatments. About 25 children will take part, and the study lasts 68 weeks.

This study tests whether adding sirolimus to standard lupus therapy helps control active disease better than a placebo. It involves 146 adults with lupus who still have symptoms despite usual care. The main goal is to see if more people achieve a meaningful reduction in disease a…

This study tests a new medicine called ianalumab, given as a monthly shot, for people with active systemic lupus erythematosus (SLE). The goal is to see if adding ianalumab to standard treatments can better control lupus symptoms and reduce flares. About 288 participants aged 12 …

This study looks at the long-term safety of a drug called dapirolizumab pegol for people with systemic lupus erythematosus (lupus). About 760 adults who completed a previous related study will receive the drug and be monitored for side effects. The goal is to see if the drug is s…

This study tests a non-invasive device that uses low-frequency electromagnetic waves to help immune cells communicate better. The goal is to reduce flare-ups in people with lupus, rheumatoid arthritis, or multiple sclerosis. 120 adults will receive either real or placebo sessions…

This study looks at whether the Shingrix vaccine is safe and effective for people with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who have a higher risk of shingles. About 2,000 participants will receive the vaccine or no vaccine, and researchers will moni…

This study is the first time the experimental drug GSK4347859 is given to humans. It aims to check the drug's safety and how it behaves in the body, not to treat any disease. About 65 healthy adults will receive either the drug or a placebo. The trial is currently on hold.

This study planned to follow women with rare autoimmune diseases (like lupus or arthritis) through pregnancy to learn about complications and improve care. It was withdrawn before any participants enrolled, so no results are available. The goal was to gather information to help d…

This study looks at 500 adults with lupus to see if certain immune system markers can better predict who is at high risk for heart disease. Researchers will track changes in artery health over time using ultrasound. The goal is to improve heart risk assessment beyond traditional …

This study tests a program called HOP-STEP that helps doctors better discuss pregnancy prevention and planning with women who have lupus. The program was already successful at one hospital, and now researchers are adapting it for use at other centers. The goal is to see if it imp…